Suppr超能文献

胆汁酸与法尼醇X受体:肝脏疾病的新靶点

Bile Acids and FXR: Novel Targets for Liver Diseases.

作者信息

Stofan Mary, Guo Grace L

机构信息

Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, United States.

Environmental and Occupational Health Sciences Institute, Rutgers, The State University of New Jersey, Piscataway, NJ, United States.

出版信息

Front Med (Lausanne). 2020 Sep 11;7:544. doi: 10.3389/fmed.2020.00544. eCollection 2020.

Abstract

Bile acids (BAs) are evolutionally conserved molecules synthesized in the liver from cholesterol and have been shown to be essential for lipid homeostasis. BAs regulate a variety of metabolic functions modulating nuclear and membrane receptors. Farnesoid X receptor (FXR) is the most important nuclear receptor for maintaining BA homeostasis. FXR plays a tissue-specific role in suppressing BA synthesis and promoting BA enterohepatic circulation. Disruption of FXR in mice have been implicated in liver diseases commonly occurring in humans, including cholestasis, non-alcoholic fatty liver diseases, and hepatocellular carcinoma. Strategically targeting FXR activity has been rapidly used to develop novel therapies for the prevention and/or treatment of cholestasis and non-alcoholic steatohepatitis. This review provides an updated literature review on BA homeostasis and FXR modulator development.

摘要

胆汁酸(BAs)是在肝脏中由胆固醇合成的进化保守分子,已被证明对脂质稳态至关重要。胆汁酸调节多种代谢功能,调节核受体和膜受体。法尼酯X受体(FXR)是维持胆汁酸稳态最重要的核受体。FXR在抑制胆汁酸合成和促进胆汁酸肠肝循环中发挥组织特异性作用。小鼠中FXR的破坏与人类常见的肝脏疾病有关,包括胆汁淤积、非酒精性脂肪性肝病和肝细胞癌。战略性地靶向FXR活性已迅速用于开发预防和/或治疗胆汁淤积和非酒精性脂肪性肝炎的新疗法。本综述提供了关于胆汁酸稳态和FXR调节剂开发的最新文献综述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889a/7516013/d758c4680b96/fmed-07-00544-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验